$0.98
5.77%
Nasdaq, Nov 19, 03:59 pm EST. Closed.
ISIN
US30205M1018
Symbol
XCUR

Exicure Inc Stock price

$0.98
-0.05 4.85% 1M
-1.91 66.09% 6M
-4.44 81.92% YTD
-3.76 79.32% 1Y
-1.80 64.72% 3Y
-68.02 98.58% 5Y
-464.02 99.79% 10Y
-464.02 99.79% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
-0.06 5.77%
ISIN
US30205M1018
Symbol
XCUR
Industry

Is Exicure Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.1m
Enterprise Value
$2.4m
Net debt
positive
Cash
$1.7m
Shares outstanding
6.4m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | -
P/B
4.2
Financial Health
Equity Ratio
28.0%
Return on Equity
-126.0%
ROCE
-101.1%
ROIC
-
Debt/Equity
0.0
Financials
Revenue | estimate
$0.0 | -
EBITDA
$-7.1m
EBIT
$-7.3m
Net Income
$-8.3m
Free Cash Flow | ex SBC
$-6.7m | -
Growth
Revenue | estimate
- | -
EBITDA
13.4%
EBIT
12.5%
Net Income
-5.1%
Free Cash Flow
-22.0%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-1.3
FCF per Share
$-1.1
Short interest
1.6%
Employees
8
Rev per Employee
$0.0

Exicure Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Exicure Inc forecast:

Hold
50%
Sell
50%

Financial data from Exicure Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.28 5.28
20% 20%
-
- Research and Development Expense 2.03 2.03
17% 17%
-
-7.11 -7.11
13% 13%
-
- Depreciation and Amortization 0.20 0.20
33% 33%
-
EBIT (Operating Income) EBIT -7.31 -7.31
12% 12%
-
Net Profit -8.28 -8.28
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Exicure Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exicure Inc Stock News

Neutral
GlobeNewsWire
●
3 days ago
WILMINGTON, Del., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it filed a Notification of Late Filing on Form 12b-25 with the Securities and Exchange Commission (the “SEC”) with respect to its Quarterly Report on Form 10-Q for the three months ended September 30, 2026 (the “Form 10-Q”).
Neutral
GlobeNewsWire
●
9 days ago
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws o...
Neutral
GlobeNewsWire
●
2 months ago
WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).
More Exicure Inc News

Company Profile

Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

Head office United States
CEO Mr. Kim
Employees 8
Founded 2011
Website www.exicuretx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today